{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:58:35Z","timestamp":1793285915795,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA050558"],"award-info":[{"award-number":["T32 DA050558"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F30 DA062492"],"award-info":[{"award-number":["F30 DA062492"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U18 DA052416"],"award-info":[{"award-number":["U18 DA052416"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA058493"],"award-info":[{"award-number":["R01 DA058493"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U18 DA052416"],"award-info":[{"award-number":["U18 DA052416"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA058493"],"award-info":[{"award-number":["R01 DA058493"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA058493"],"award-info":[{"award-number":["R01 DA058493"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U18 DA052416"],"award-info":[{"award-number":["U18 DA052416"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA051831"],"award-info":[{"award-number":["R01 DA051831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T32DT5202"],"award-info":[{"award-number":["T32DT5202"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tobacco use remains the leading cause of preventable death worldwide. Unfortunately, currently available cessation aids have limited long-term efficacy. GPR3 is a G\u03b1s coupled receptor expressed in discrete brain regions, with notably high expression in cholinergic neurons of the medial habenula. Here, we investigated whether modulation of GPR3 could be a viable target for therapeutic development to promote nicotine cessation. We first examined whether our recently developed GPR3 receptor agonist, RTI-19318-32, could induce effects on intravenous nicotine self-administration at low, moderate or high nicotine doses in mice. We found that in both males and females, RTI-19318-32 significantly reduced nicotine intake at all self-administered nicotine doses, thereby supporting the validity of this therapeutic approach for individuals using varying levels of daily nicotine. RTI-19318-32 was further validated as being selective for GPR3, as it did not alter nicotine intake in GPR3 knockout mice, nor did it exert effects on anxiety-associated behavior or locomotion. While the higher RTI-19318-32 dose attenuated food-related reinforcement behavior, it was ineffective in altering baseline food consumption. Moreover, the lower RTI-19318-32 dose did not alter food reinforcement behavior, indicating selectivity in mediating nicotine intake. Finally, GPR3 expression co-localized with multiple nAChR subunits in the medial habenula, thereby supporting our proposed targeted approach for circuit engagement intentionally directed at modulating the drive to consume nicotine. Taken together, these data reveal the functional significance of agonist-inducted activation of the GPR3 receptor and establish the validity of focusing on therapeutic development of GPR3 ligands for nicotine cessation.<\/jats:p>","DOI":"10.1038\/s41386-025-02202-3","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:34:56Z","timestamp":1756283696000},"page":"2051-2062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting GPR3 as a novel approach for nicotine cessation therapeutic development"],"prefix":"10.1038","volume":"50","author":[{"given":"Allison S.","family":"Mogul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendyl N.","family":"Laumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malia","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JP","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-2163","authenticated-orcid":false,"given":"Christie D.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"2202_CR1","unstructured":"World Health Organization. WHO Report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. 2017. Accessed at https:\/\/www.who.int\/publications\/i\/item\/9789241512824"},{"key":"2202_CR2","unstructured":"Center for Disease Control. CDC 2014 Surgeon general\u2019s report: the health consequences of smoking\u201450 years of progress. 2014. Accessed at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK179276\/"},{"key":"2202_CR3","unstructured":"U.S. Department of Health and Human Services. Smoking cessation: a report of the surgeon general\u2014key findings. 2020. Accessed at https:\/\/www.hhs.gov\/surgeongeneral\/reports-and-publications\/tobacco\/2020-cessation-sgr-factsheet-key-findings\/index.html"},{"key":"2202_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/tobaccocontrol-2020-056371","volume":"32","author":"D Hammond","year":"2021","unstructured":"Hammond D, Reid JL, Burkhalter R, O\u2019Connor RJ, Goniewicz ML, Wackowski OA, et al. Trends in e-cigarette brands, devices and the nicotine profile of products used by youth in England, Canada and the USA: 2017-2019. Tob control. 2021;32:19\u201329.","journal-title":"Tob control"},{"key":"2202_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00038-015-0761-0","volume":"61","author":"SR Weaver","year":"2016","unstructured":"Weaver SR, Majeed BA, Pechacek TF, Nyman AL, Gregory KR, Eriksen MP. Use of electronic nicotine delivery systems and other tobacco products among USA adults, 2014: results from a national survey. Int J Public Health. 2016;61:177\u201388.","journal-title":"Int J Public Health"},{"key":"2202_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/0033354919864369","volume":"134","author":"R McMillen","year":"2019","unstructured":"McMillen R, Klein JD, Wilson K, Winickoff JP, Tanski S. E-cigarette use and future cigarette initiation among never smokers and relapse among former smokers in the PATH study. Public health Rep. 2019;134:528\u201336.","journal-title":"Public health Rep"},{"key":"2202_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/ntr\/ntz062","volume":"22","author":"RL Rosen","year":"2020","unstructured":"Rosen RL, Steinberg ML. Interest in quitting e-cigarettes among adults in the United States. Nicotine Tob Res. 2020;22:857\u201358.","journal-title":"Nicotine Tob Res"},{"key":"2202_CR8","volume":"15","author":"DD Pajai","year":"2023","unstructured":"Pajai DD, Paul P, Reche A. Pharmacotherapy in tobacco cessation: a narrative review. Cureus. 2023;15:e35086.","journal-title":"Cureus"},{"key":"2202_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2022.0395","volume":"327","author":"NA Rigotti","year":"2022","unstructured":"Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of tobacco smoking: a review. J Am Med Assoc. 2022;327:566\u201377.","journal-title":"J Am Med Assoc"},{"key":"2202_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/mol.117.111062","volume":"93","author":"K Sriram","year":"2018","unstructured":"Sriram K, Insel PA. G Protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol Pharm. 2018;93:251\u201358.","journal-title":"Mol Pharm"},{"key":"2202_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1042\/bj3090837","volume":"309","author":"D Eggerickx","year":"1995","unstructured":"Eggerickx D, Denef JF, Labbe O, Hayashi Y, Refetoff S, Vassart G, et al. Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. Biochem J. 1995;309:837\u201343.","journal-title":"Biochem J"},{"key":"2202_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41422-024-00932-5","volume":"34","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Xu Z, Li X, Wang Y, Zhao J, Wang N, et al. Identification of oleic acid as an endogenous ligand of GPR3. Cell Res. 2024;34:232\u201344.","journal-title":"Cell Res"},{"key":"2202_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147166","volume":"1750","author":"F Ikawa","year":"2021","unstructured":"Ikawa F, Tanaka S, Harada K, Hide I, Maruyama H, Sakai N. Detailed neuronal distribution of GPR3 and its co-expression with EF-hand calcium-binding proteins in the mouse central nervous system. Brain Res. 2021;1750:147166.","journal-title":"Brain Res"},{"key":"2202_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nature09797","volume":"471","author":"CD Fowler","year":"2011","unstructured":"Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular \u03b15 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011;471:597\u2013601.","journal-title":"Nature"},{"key":"2202_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nature09797","volume":"471","author":"CD Fowler","year":"2011","unstructured":"Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011;471:597\u2013601.","journal-title":"Nature"},{"key":"2202_CR16","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1523\/JNEUROSCI.0127-19.2020","volume":"41","author":"KS Elayouby","year":"2021","unstructured":"Elayouby KS, Ishikawa M, Dukes AJ, Smith ACW, Lu Q, Fowler CD, et al. alpha3* nicotinic acetylcholine receptors in the habenula-interpeduncular nucleus circuit regulate nicotine intake. J Neurosci. 2021;41:1779\u201387.","journal-title":"J Neurosci"},{"key":"2202_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129427","volume":"94","author":"EA Gay","year":"2023","unstructured":"Gay EA, Harris DL, Wilson JW, Blough BE. The development of diphenyleneiodonium analogs as GPR3 agonists. Bioorg Med Chem Lett. 2023;94:129427.","journal-title":"Bioorg Med Chem Lett"},{"key":"2202_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep14953","volume":"5","author":"G Godlewski","year":"2015","unstructured":"Godlewski G, Jourdan T, Szanda G, Tam J, Resat C, Harvey-White J, et al. Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue. Sci Rep. 2015;5:14953.","journal-title":"Sci Rep"},{"key":"2202_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.neuropharm.2011.05.012","volume":"61","author":"CD Fowler","year":"2011","unstructured":"Fowler CD, Kenny PJ. Intravenous nicotine self-administration and cue-induced reinstatement in mice: effects of nicotine dose, rate of drug infusion and prior instrumental training. Neuropharmacology. 2011;61:687\u201398.","journal-title":"Neuropharmacology"},{"key":"2202_CR20","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1523\/JNEUROSCI.1433-17.2018","volume":"38","author":"E Chen","year":"2018","unstructured":"Chen E, Lallai V, Sherafat Y, Grimes NP, Pushkin AN, Fowler JP, et al. Altered baseline and nicotine-mediated behavioral and cholinergic profiles in ChAT-Cre mouse lines. J Neurosci : J Soc Neurosci. 2018;38:2177\u201388.","journal-title":"J Neurosci : J Soc Neurosci"},{"key":"2202_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41586-023-06818-7","volume":"624","author":"J Langlieb","year":"2023","unstructured":"Langlieb J, Sachdev NS, Balderrama KS, Nadaf NM, Raj M, Murray E, et al. The molecular cytoarchitecture of the adult mouse brain. Nature. 2023;624:333\u201342.","journal-title":"Nature"},{"key":"2202_CR22","doi-asserted-by":"publisher","first-page":"11045","DOI":"10.1523\/JNEUROSCI.23-35-11045.2003","volume":"23","author":"C Cui","year":"2003","unstructured":"Cui C, Booker TK, Allen RS, Grady SR, Whiteaker P, Marks MJ, et al. The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J Neurosci. 2003;23:11045\u201353.","journal-title":"J Neurosci"},{"key":"2202_CR23","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/S0028-3908(00)00138-6","volume":"39","author":"EB Sheffield","year":"2000","unstructured":"Sheffield EB, Quick MW, Lester RA. Nicotinic acetylcholine receptor subunit mRNA expression and channel function in medial habenula neurons. Neuropharmacology. 2000;39:2591\u2013603.","journal-title":"Neuropharmacology"},{"key":"2202_CR24","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1016\/j.cell.2021.04.037","volume":"184","author":"O Sveidahl Johansen","year":"2021","unstructured":"Sveidahl Johansen O, Ma T, Hansen JB, Markussen LK, Schreiber R, Reverte-Salisa L, et al. Lipolysis drives expression of the constitutively active receptor GPR3 to induce adipose thermogenesis. Cell. 2021;184:3502\u201318.e33.","journal-title":"Cell"},{"key":"2202_CR25","doi-asserted-by":"publisher","first-page":"e4704","DOI":"10.1371\/journal.pone.0004704","volume":"4","author":"O Valverde","year":"2009","unstructured":"Valverde O, C\u00e9l\u00e9rier E, Baranyi M, Vanderhaeghen P, Maldonado R, Sperlagh B, et al. GPR3 receptor, a novel actor in the emotional-like responses. PLoS ONE. 2009;4:e4704.","journal-title":"PLoS ONE"},{"key":"2202_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.nbd.2014.04.007","volume":"68","author":"S Tanaka","year":"2014","unstructured":"Tanaka S, Miyagi T, Dohi E, Seki T, Hide I, Sotomaru Y, et al. Developmental expression of GPR3 in rodent cerebellar granule neurons is associated with cell survival and protects neurons from various apoptotic stimuli. Neurobiol Dis. 2014;68:215\u201327.","journal-title":"Neurobiol Dis"},{"key":"2202_CR27","doi-asserted-by":"publisher","first-page":"e5922","DOI":"10.1371\/journal.pone.0005922","volume":"4","author":"S Tanaka","year":"2009","unstructured":"Tanaka S, Shaikh IM, Chiocca EA, Saeki Y. The Gs-linked receptor GPR3 inhibits the proliferation of cerebellar granule cells during postnatal development. PLoS ONE. 2009;4:e5922.","journal-title":"PLoS ONE"},{"key":"2202_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2021.103691","volume":"118","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Shimada N, Shiraki H, Miyagi T, Harada K, Hide I, et al. GPR3 accelerates neurite outgrowth and neuronal polarity formation via PI3 kinase-mediating signaling pathway in cultured primary neurons. Mol Cell Neurosci. 2022;118:103691.","journal-title":"Mol Cell Neurosci"},{"key":"2202_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1476-5381.2012.02043.x","volume":"167","author":"C Tourino","year":"2012","unstructured":"Tourino C, Valjent E, Ruiz-Medina J, Herve D, Ledent C, Valverde O. The orphan receptor GPR3 modulates the early phases of cocaine reinforcement. Br J Pharm. 2012;167:892\u2013904.","journal-title":"Br J Pharm"},{"key":"2202_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1134079","volume":"14","author":"M Bautista","year":"2023","unstructured":"Bautista M, Mogul AS, Fowler CD. Beyond the label: current evidence and future directions for the interrelationship between electronic cigarettes and mental health. Front psychiatry. 2023;14:1134079.","journal-title":"Front psychiatry"},{"key":"2202_CR31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cmet.2021.06.003","volume":"33","author":"M Balaz","year":"2021","unstructured":"Balaz M, Wolfrum C. GPR3 sets brown fat on fire. Cell Metab. 2021;33:1271\u201373.","journal-title":"Cell Metab"},{"key":"2202_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrendo.2016.32","volume":"12","author":"KK Harris","year":"2016","unstructured":"Harris KK, Zopey M, Friedman TC. Metabolic effects of smoking cessation. Nat Rev. Endocrinol. 2016;12:299\u2013308.","journal-title":"Nat Rev. Endocrinol"},{"key":"2202_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2021.12.064","volume":"588","author":"K Takeda","year":"2022","unstructured":"Takeda K, Aotani D, Kuga Y, Jinno T, Guo T, Ogawa K, et al. A mouse model of weight gain after nicotine withdrawal. Biochem Biophys Res. Commun. 2022;588:140\u201346.","journal-title":"Biochem Biophys Res. Commun"},{"key":"2202_CR34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ypmed.2006.11.014","volume":"44","author":"C Pisinger","year":"2007","unstructured":"Pisinger C, Jorgensen T. Weight concerns and smoking in a general population: the Inter99 study. Prev Med. 2007;44:283\u20139.","journal-title":"Prev Med"},{"key":"2202_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41422-023-00919-8","volume":"34","author":"G Chen","year":"2024","unstructured":"Chen G, Staffen N, Wu Z, Xu X, Pan J, Inoue A, et al. Structural and functional characterization of the endogenous agonist for orphan receptor GPR3. Cell Res. 2024;34:262\u201365.","journal-title":"Cell Res"},{"key":"2202_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47057-z","volume":"9","author":"J Song","year":"2019","unstructured":"Song J, Kim YS, Lee DH, Lee SH, Park HJ, Lee D, et al. Neuroprotective effects of oleic acid in rodent models of cerebral ischaemia. Sci Rep. 2019;9:10732.","journal-title":"Sci Rep"},{"key":"2202_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1750-3639.2010.00449.x","volume":"21","author":"Z Amtul","year":"2011","unstructured":"Amtul Z, Westaway D, Cechetto DF, Rozmahel RF. Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer\u2019s disease. Brain Pathol. 2011;21:321\u20139.","journal-title":"Brain Pathol"},{"key":"2202_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1471-4159.2001.00598.x","volume":"79","author":"A Tabernero","year":"2001","unstructured":"Tabernero A, Lavado EM, Granda B, Velasco A, Medina JM. Neuronal differentiation is triggered by oleic acid synthesized and released by astrocytes. J Neurochem. 2001;79:606\u201316.","journal-title":"J Neurochem"},{"key":"2202_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1124\/jpet.119.260653","volume":"372","author":"YC Chen","year":"2020","unstructured":"Chen YC, Fowler JP, Wang J, Watson CJW, Sherafat Y, Staben A, et al. The novel CYP2A6 inhibitor, DLCI-1, decreases nicotine self-administration in mice. J Pharm Exp Ther. 2020;372:21\u201329.","journal-title":"J Pharm Exp Ther"},{"key":"2202_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pbb.2015.01.009","volume":"130","author":"BJ Hall","year":"2015","unstructured":"Hall BJ, Slade S, Wells C, Rose JE, Levin ED. Bupropion-varenicline interactions and nicotine self-administration behavior in rats. Pharm Biochem Behav. 2015;130:84\u20139.","journal-title":"Pharm Biochem Behav"},{"key":"2202_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00213-009-1739-5","volume":"208","author":"EC O\u2019Connor","year":"2010","unstructured":"O\u2019Connor EC, Parker D, Rollema H, Mead AN. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology. 2010;208:365\u201376.","journal-title":"Psychopharmacology"},{"key":"2202_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0005-2728(70)90154-4","volume":"216","author":"LE Bakeeva","year":"1970","unstructured":"Bakeeva LE, Grinius LL, Jasaitis AA, Kuliene VV, Levitsky DO, Liberman EA, et al. Conversion of biomembrane-produced energy into electric form. II. Intact mitochondria. Biochim Biophys Acta. 1970;216:13\u201321.","journal-title":"Biochim Biophys Acta"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02202-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:04:27Z","timestamp":1762808667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02202-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2202"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02202-3","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest to disclose. CDF serves on the scientific advisory board of a therapeutic development company, GATC Health, which is unrelated to the research presented herein.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}